 Stephen Waldo
Concepts (415)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 77 | 2025 | 478 | 19.450 |
Why?
| | Coronary Artery Disease | 45 | 2025 | 701 | 10.980 |
Why?
| | United States Department of Veterans Affairs | 32 | 2025 | 667 | 5.840 |
Why?
| | Coronary Angiography | 31 | 2025 | 314 | 3.730 |
Why?
| | Myocardial Infarction | 29 | 2025 | 1044 | 3.420 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 474 | 3.380 |
Why?
| | Endovascular Procedures | 18 | 2020 | 310 | 3.280 |
Why?
| | Femoral Artery | 13 | 2022 | 178 | 2.820 |
Why?
| | Veterans | 18 | 2025 | 1446 | 2.800 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 275 | 2.800 |
Why?
| | Treatment Outcome | 91 | 2025 | 10768 | 2.780 |
Why?
| | Vascular Calcification | 9 | 2022 | 108 | 2.440 |
Why?
| | Veterans Health | 7 | 2025 | 180 | 2.370 |
Why?
| | Stents | 21 | 2019 | 524 | 2.310 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 54 | 2.210 |
Why?
| | Popliteal Artery | 11 | 2020 | 59 | 2.190 |
Why?
| | Registries | 28 | 2023 | 2006 | 2.060 |
Why?
| | Coronary Artery Bypass | 8 | 2025 | 237 | 2.020 |
Why?
| | Atherectomy | 11 | 2022 | 37 | 2.020 |
Why?
| | Risk Factors | 70 | 2025 | 10313 | 2.010 |
Why?
| | Ischemia | 11 | 2020 | 407 | 1.840 |
Why?
| | United States | 62 | 2025 | 14595 | 1.820 |
Why?
| | Time Factors | 52 | 2025 | 6802 | 1.790 |
Why?
| | Aged | 88 | 2025 | 23641 | 1.770 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 10 | 1.760 |
Why?
| | Risk Assessment | 29 | 2025 | 3432 | 1.730 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2025 | 454 | 1.660 |
Why?
| | Time-to-Treatment | 5 | 2024 | 200 | 1.610 |
Why?
| | Radial Artery | 7 | 2022 | 69 | 1.610 |
Why?
| | Lower Extremity | 4 | 2018 | 423 | 1.600 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 140 | 1.590 |
Why?
| | Middle Aged | 82 | 2025 | 33118 | 1.480 |
Why?
| | Hospitals, Veterans | 5 | 2025 | 248 | 1.440 |
Why?
| | Humans | 158 | 2025 | 136898 | 1.370 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 160 | 1.370 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 21 | 1.330 |
Why?
| | Hospital Mortality | 13 | 2025 | 901 | 1.300 |
Why?
| | Biological Products | 2 | 2023 | 219 | 1.290 |
Why?
| | Male | 101 | 2025 | 67308 | 1.240 |
Why?
| | Coronary Vessels | 7 | 2025 | 245 | 1.230 |
Why?
| | Coronary Restenosis | 4 | 2017 | 21 | 1.220 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 93 | 1.200 |
Why?
| | Myocardial Ischemia | 5 | 2025 | 263 | 1.170 |
Why?
| | Female | 95 | 2025 | 72703 | 1.120 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 73 | 1.110 |
Why?
| | Retrospective Studies | 53 | 2025 | 15514 | 1.100 |
Why?
| | Access to Information | 2 | 2019 | 49 | 1.080 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 111 | 1.060 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 256 | 0.980 |
Why?
| | Angina, Stable | 3 | 2022 | 17 | 0.950 |
Why?
| | Patient Readmission | 9 | 2025 | 693 | 0.940 |
Why?
| | Eligibility Determination | 1 | 2025 | 65 | 0.910 |
Why?
| | Quality Improvement | 5 | 2025 | 1154 | 0.900 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 62 | 0.900 |
Why?
| | Cardiology | 4 | 2022 | 271 | 0.890 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2025 | 258 | 0.880 |
Why?
| | Quality of Health Care | 3 | 2025 | 626 | 0.870 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 50 | 0.850 |
Why?
| | Community Health Services | 1 | 2025 | 232 | 0.840 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 528 | 0.830 |
Why?
| | Stroke Volume | 3 | 2021 | 611 | 0.810 |
Why?
| | Vascular Patency | 14 | 2020 | 105 | 0.810 |
Why?
| | Chickens | 1 | 2023 | 192 | 0.790 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 540 | 0.790 |
Why?
| | Heart Arrest | 3 | 2017 | 335 | 0.780 |
Why?
| | Vascular Access Devices | 5 | 2020 | 26 | 0.760 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 25 | 0.760 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 182 | 0.760 |
Why?
| | Psoriasis | 1 | 2023 | 102 | 0.760 |
Why?
| | Healthcare Disparities | 3 | 2024 | 632 | 0.750 |
Why?
| | California | 18 | 2019 | 423 | 0.740 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 438 | 0.730 |
Why?
| | Aged, 80 and over | 23 | 2025 | 7552 | 0.730 |
Why?
| | Practice Patterns, Physicians' | 7 | 2025 | 1310 | 0.720 |
Why?
| | Anemia | 2 | 2022 | 171 | 0.710 |
Why?
| | Coronary Occlusion | 2 | 2023 | 19 | 0.710 |
Why?
| | Patient Selection | 1 | 2025 | 690 | 0.710 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 25 | 0.700 |
Why?
| | Hemorrhage | 5 | 2022 | 718 | 0.680 |
Why?
| | Hospitals, Community | 1 | 2020 | 50 | 0.670 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 81 | 0.660 |
Why?
| | Assisted Circulation | 1 | 2019 | 26 | 0.650 |
Why?
| | Paclitaxel | 2 | 2019 | 231 | 0.650 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 47 | 0.640 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2110 | 0.630 |
Why?
| | Postoperative Complications | 5 | 2025 | 2627 | 0.620 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 12 | 0.620 |
Why?
| | Quality Indicators, Health Care | 4 | 2025 | 310 | 0.620 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 17 | 0.620 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 88 | 0.620 |
Why?
| | Saphenous Vein | 1 | 2019 | 35 | 0.610 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 42 | 0.610 |
Why?
| | Databases, Factual | 11 | 2025 | 1345 | 0.610 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 531 | 0.610 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 271 | 0.590 |
Why?
| | Electrocardiography | 4 | 2015 | 632 | 0.590 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 81 | 0.570 |
Why?
| | Arm | 1 | 2018 | 106 | 0.560 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 103 | 0.560 |
Why?
| | Odds Ratio | 8 | 2021 | 1063 | 0.560 |
Why?
| | Propensity Score | 6 | 2024 | 287 | 0.550 |
Why?
| | Thromboembolism | 1 | 2018 | 119 | 0.550 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 892 | 0.540 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 96 | 0.540 |
Why?
| | Limb Salvage | 7 | 2019 | 60 | 0.540 |
Why?
| | Embolism | 1 | 2017 | 41 | 0.530 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 30 | 0.530 |
Why?
| | Renal Artery | 1 | 2017 | 37 | 0.520 |
Why?
| | Aspirin | 2 | 2019 | 385 | 0.520 |
Why?
| | Contrast Media | 4 | 2025 | 462 | 0.520 |
Why?
| | Heart Failure | 6 | 2023 | 2210 | 0.520 |
Why?
| | Research Report | 1 | 2017 | 83 | 0.510 |
Why?
| | Hospitals | 4 | 2023 | 678 | 0.510 |
Why?
| | Transcatheter Aortic Valve Replacement | 3 | 2025 | 129 | 0.500 |
Why?
| | Catheterization | 3 | 2021 | 178 | 0.490 |
Why?
| | Coronary Stenosis | 5 | 2020 | 38 | 0.480 |
Why?
| | Hospitalization | 4 | 2025 | 2183 | 0.470 |
Why?
| | Iliac Artery | 4 | 2019 | 56 | 0.470 |
Why?
| | Hypertension, Pulmonary | 5 | 2025 | 1901 | 0.450 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 219 | 0.450 |
Why?
| | Disclosure | 1 | 2015 | 112 | 0.440 |
Why?
| | Thrombectomy | 2 | 2014 | 64 | 0.430 |
Why?
| | Cell Separation | 1 | 2015 | 319 | 0.430 |
Why?
| | Cohort Studies | 10 | 2023 | 5711 | 0.420 |
Why?
| | Atherosclerosis | 3 | 2019 | 411 | 0.420 |
Why?
| | Depressive Disorder | 1 | 2017 | 383 | 0.420 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 298 | 0.410 |
Why?
| | Cardiologists | 2 | 2025 | 46 | 0.400 |
Why?
| | Predictive Value of Tests | 9 | 2025 | 2030 | 0.400 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 807 | 0.400 |
Why?
| | Disease Management | 1 | 2017 | 624 | 0.390 |
Why?
| | Survival Rate | 6 | 2021 | 1972 | 0.390 |
Why?
| | Incidence | 8 | 2025 | 2783 | 0.380 |
Why?
| | Peer Review | 2 | 2025 | 50 | 0.380 |
Why?
| | HIV | 1 | 2013 | 232 | 0.380 |
Why?
| | Logistic Models | 6 | 2017 | 2060 | 0.370 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1160 | 0.370 |
Why?
| | Intermittent Claudication | 3 | 2017 | 118 | 0.370 |
Why?
| | Hypothermia | 1 | 2011 | 36 | 0.360 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2024 | 72 | 0.360 |
Why?
| | Stroke | 7 | 2025 | 1122 | 0.340 |
Why?
| | Cause of Death | 3 | 2023 | 431 | 0.340 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2833 | 0.330 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 228 | 0.320 |
Why?
| | Mentoring | 2 | 2023 | 144 | 0.320 |
Why?
| | Endothelial Cells | 1 | 2015 | 779 | 0.310 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1262 | 0.310 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 242 | 0.310 |
Why?
| | Mortality | 3 | 2020 | 357 | 0.310 |
Why?
| | Peptide Fragments | 2 | 2015 | 707 | 0.310 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 533 | 0.300 |
Why?
| | Punctures | 2 | 2019 | 40 | 0.290 |
Why?
| | Angiography | 6 | 2020 | 208 | 0.290 |
Why?
| | Laser Therapy | 2 | 2019 | 134 | 0.280 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 100 | 0.280 |
Why?
| | Carotid Stenosis | 2 | 2018 | 91 | 0.270 |
Why?
| | Emergency Medical Services | 1 | 2013 | 545 | 0.270 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 40 | 0.260 |
Why?
| | Recurrence | 9 | 2019 | 1058 | 0.260 |
Why?
| | HIV Infections | 3 | 2023 | 2822 | 0.250 |
Why?
| | Sex Factors | 5 | 2025 | 2067 | 0.250 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 389 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1524 | 0.250 |
Why?
| | Ultrasonography, Interventional | 2 | 2025 | 142 | 0.240 |
Why?
| | Acute Disease | 3 | 2017 | 1000 | 0.240 |
Why?
| | Macrophages | 3 | 2008 | 1547 | 0.240 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 66 | 0.240 |
Why?
| | Patient Discharge | 3 | 2022 | 887 | 0.240 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2025 | 24 | 0.240 |
Why?
| | Peer Review, Health Care | 1 | 2025 | 4 | 0.240 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 608 | 0.240 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 210 | 0.230 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 80 | 0.230 |
Why?
| | Chest Pain | 3 | 2022 | 91 | 0.230 |
Why?
| | Health Services Accessibility | 2 | 2025 | 964 | 0.230 |
Why?
| | Travel | 1 | 2025 | 130 | 0.220 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5126 | 0.220 |
Why?
| | Comorbidity | 5 | 2020 | 1611 | 0.220 |
Why?
| | Pancreas | 2 | 2004 | 328 | 0.220 |
Why?
| | Prosthesis Failure | 2 | 2016 | 116 | 0.210 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 79 | 0.210 |
Why?
| | Hypertension, Portal | 1 | 2024 | 64 | 0.210 |
Why?
| | Coronary Circulation | 2 | 2014 | 141 | 0.210 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5398 | 0.200 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2025 | 182 | 0.200 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 9 | 0.200 |
Why?
| | Biological Therapy | 1 | 2023 | 29 | 0.200 |
Why?
| | New York | 3 | 2017 | 133 | 0.200 |
Why?
| | Prognosis | 6 | 2021 | 4011 | 0.190 |
Why?
| | Work Engagement | 1 | 2022 | 10 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 320 | 0.190 |
Why?
| | Chronic Disease | 5 | 2023 | 1773 | 0.190 |
Why?
| | Leukocytes | 1 | 2003 | 311 | 0.190 |
Why?
| | Technology Transfer | 1 | 2021 | 10 | 0.180 |
Why?
| | Critical Illness | 8 | 2020 | 805 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 277 | 0.180 |
Why?
| | Hemodynamics | 4 | 2024 | 1114 | 0.180 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 63 | 0.170 |
Why?
| | Anticoagulants | 2 | 2016 | 662 | 0.170 |
Why?
| | Angina Pectoris | 1 | 2020 | 66 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 210 | 0.170 |
Why?
| | Mandatory Reporting | 2 | 2017 | 45 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2022 | 198 | 0.160 |
Why?
| | Patient Care Team | 1 | 2025 | 624 | 0.160 |
Why?
| | Exercise Test | 2 | 2022 | 621 | 0.160 |
Why?
| | Massachusetts | 2 | 2017 | 167 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2025 | 779 | 0.160 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 25 | 0.160 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1434 | 0.160 |
Why?
| | Health Facilities | 1 | 2019 | 83 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 65 | 0.150 |
Why?
| | Intraoperative Period | 1 | 2019 | 59 | 0.150 |
Why?
| | Vascular Resistance | 1 | 2020 | 372 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2023 | 948 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2020 | 147 | 0.150 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.150 |
Why?
| | Heart | 1 | 2022 | 660 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1279 | 0.150 |
Why?
| | Thrombosis | 1 | 2022 | 368 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 229 | 0.150 |
Why?
| | Colorado | 8 | 2019 | 4491 | 0.150 |
Why?
| | Perioperative Care | 1 | 2020 | 182 | 0.140 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.140 |
Why?
| | Perception | 1 | 2021 | 359 | 0.140 |
Why?
| | Transportation of Patients | 1 | 2018 | 54 | 0.140 |
Why?
| | Disease-Free Survival | 5 | 2017 | 690 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 4148 | 0.140 |
Why?
| | Angioplasty | 1 | 2018 | 47 | 0.140 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.140 |
Why?
| | Cardiac Catheters | 1 | 2017 | 15 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2508 | 0.140 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 22 | 0.140 |
Why?
| | Algorithms | 2 | 2017 | 1695 | 0.140 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 7 | 0.140 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 21 | 0.140 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1084 | 0.140 |
Why?
| | Clinical Competence | 1 | 2025 | 1086 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 984 | 0.130 |
Why?
| | Neck | 1 | 2017 | 101 | 0.130 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 21 | 0.130 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 37 | 0.130 |
Why?
| | Risk | 2 | 2019 | 905 | 0.130 |
Why?
| | Suction | 2 | 2014 | 34 | 0.130 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3282 | 0.130 |
Why?
| | Policy Making | 1 | 2017 | 98 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 270 | 0.130 |
Why?
| | Flow Cytometry | 2 | 2015 | 1185 | 0.130 |
Why?
| | Aortic Valve | 1 | 2019 | 352 | 0.130 |
Why?
| | Adult | 7 | 2024 | 37595 | 0.130 |
Why?
| | Boston | 1 | 2016 | 92 | 0.130 |
Why?
| | Academic Medical Centers | 2 | 2016 | 494 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2017 | 177 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 440 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1615 | 0.120 |
Why?
| | Cholesterol | 2 | 2008 | 412 | 0.120 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 220 | 0.120 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
| | Antithrombins | 1 | 2015 | 59 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 116 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1769 | 0.110 |
Why?
| | Collateral Circulation | 1 | 2014 | 19 | 0.110 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 195 | 0.110 |
Why?
| | Prevalence | 2 | 2019 | 2709 | 0.110 |
Why?
| | Observer Variation | 3 | 2025 | 343 | 0.100 |
Why?
| | Prospective Studies | 3 | 2020 | 7543 | 0.100 |
Why?
| | Heparin | 1 | 2015 | 259 | 0.100 |
Why?
| | Resuscitation | 1 | 2015 | 249 | 0.100 |
Why?
| | Incidental Findings | 1 | 2013 | 87 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 1033 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 195 | 0.100 |
Why?
| | Coronary Disease | 1 | 2014 | 385 | 0.090 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 75 | 0.090 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.090 |
Why?
| | Electronic Health Records | 2 | 2017 | 1018 | 0.090 |
Why?
| | Smoking Cessation | 1 | 2016 | 446 | 0.090 |
Why?
| | Antimanic Agents | 1 | 2011 | 18 | 0.090 |
Why?
| | Lithium | 1 | 2011 | 44 | 0.090 |
Why?
| | Triazines | 1 | 2011 | 43 | 0.090 |
Why?
| | Laboratories | 2 | 2022 | 111 | 0.090 |
Why?
| | American Heart Association | 2 | 2022 | 306 | 0.090 |
Why?
| | Prosthesis Design | 3 | 2017 | 309 | 0.090 |
Why?
| | Decision Support Techniques | 1 | 2014 | 413 | 0.090 |
Why?
| | Benzodiazepines | 1 | 2011 | 153 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2011 | 218 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2008 | 1975 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3290 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 119 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1402 | 0.080 |
Why?
| | Bipolar Disorder | 1 | 2011 | 270 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 703 | 0.070 |
Why?
| | Seizures | 1 | 2011 | 427 | 0.070 |
Why?
| | Pinocytosis | 1 | 2007 | 10 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 316 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 43 | 0.070 |
Why?
| | Animals | 4 | 2025 | 36914 | 0.070 |
Why?
| | Monocytes | 2 | 2007 | 567 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 151 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 386 | 0.070 |
Why?
| | Drug Overdose | 1 | 2011 | 344 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 3201 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 543 | 0.060 |
Why?
| | Inflammation | 3 | 2008 | 2817 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 324 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2175 | 0.060 |
Why?
| | Shock | 2 | 2004 | 93 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 523 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1061 | 0.060 |
Why?
| | Program Evaluation | 2 | 2019 | 889 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 509 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 2015 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1320 | 0.060 |
Why?
| | Health Plan Implementation | 1 | 2025 | 140 | 0.060 |
Why?
| | Ventricular Fibrillation | 1 | 2024 | 60 | 0.060 |
Why?
| | Trypsin | 1 | 2004 | 77 | 0.050 |
Why?
| | Amylases | 1 | 2003 | 16 | 0.050 |
Why?
| | Length of Stay | 2 | 2019 | 1203 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 132 | 0.050 |
Why?
| | Chymotrypsin | 1 | 2003 | 22 | 0.050 |
Why?
| | Ezetimibe | 1 | 2023 | 24 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1282 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 330 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 174 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1060 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 127 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 132 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 652 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2003 | 457 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 41 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1575 | 0.050 |
Why?
| | Cell Death | 1 | 2003 | 370 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 316 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2004 | 278 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 362 | 0.040 |
Why?
| | Troponin | 1 | 2021 | 51 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2025 | 528 | 0.040 |
Why?
| | Neutrophils | 2 | 2004 | 1237 | 0.040 |
Why?
| | Organizational Culture | 1 | 2022 | 144 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2744 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 497 | 0.040 |
Why?
| | Systole | 1 | 2021 | 191 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4204 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 89 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 45 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1906 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 215 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1502 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2078 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 678 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 217 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 44 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 147 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 277 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 83 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 92 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 13 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 170 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 72 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 152 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 202 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1291 | 0.040 |
Why?
| | Singapore | 1 | 2017 | 22 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 36 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5675 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1715 | 0.040 |
Why?
| | Angina, Unstable | 1 | 2017 | 76 | 0.030 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 15 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1240 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 14 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 108 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 739 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 52 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 258 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 100 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1018 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 250 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 544 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 850 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 53 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 324 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 254 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 94 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1037 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2416 | 0.030 |
Why?
| | Health Policy | 1 | 2016 | 388 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 664 | 0.020 |
Why?
| | Emergencies | 1 | 2013 | 164 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 412 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 592 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1357 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 386 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 560 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1774 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5730 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 745 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 3 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 15 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 9 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 17 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 32 | 0.020 |
Why?
| | Mice | 1 | 2025 | 17775 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 30 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 658 | 0.010 |
Why?
| | Physicians | 1 | 2013 | 902 | 0.010 |
Why?
| | Telemedicine | 1 | 2013 | 843 | 0.010 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 17 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 31 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 302 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 47 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 176 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 512 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 402 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 816 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1227 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2500 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|